Icon expands U.S. and U.K. bioanalytical labs

Monday, September 10, 2012 09:48 AM

Icon, a global provider of outsourced development services, is expanding its U.S. and U.K. bioanalytical facilities to meet the growing demand for biomarker and cell-based assay services.

Icon has increased its bioanalytical laboratories in Whitesboro, N.Y., and Manchester, U.K., by 7,000 and 4,000 square feet, respectively. The expansions allow Icon to house dedicated immunoassay laboratories at each facility for biomarker testing and cell-based assays.

“We have expanded our bioanalytical facilities to provide the necessary scale to support the ever-broadening range of testing services required by our sponsors,” said Brian O’Dwyer, senior vice president of global bioanalytical services, development solutions, Icon. “In particular, the expansion of our dedicated biomarker testing laboratories allows us to support biomarker development programs across multiple testing platforms globally.”

Operating since 1988, Icon’s Whitesboro facility already features multiple wet laboratories and instrument laboratories for small and large molecules, including a specially designed hazardous lab for the analysis of HIV and hepatitis B infected samples. Similarly, Icon’s Manchester laboratory has provided bioanalytical support for both small and large molecule studies for almost 30 years and is located close to Icon 's hospital-based clinical pharmacology unit in Manchester.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs